(Q44442609)

English

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

scientific article published in February 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

progressive relapsing multiple sclerosis

0 references

multiple sclerosis

0 references

Daniel R. Touchette

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Tracy L Durgin

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lee A Wanke

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Donald E Goodkin

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

611-634

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Revised estimate of the prevalence of multiple sclerosis in the united states

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The social impact of multiple sclerosis--a study of 305 patients and their relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comprehensive assessment of the cost of multiple sclerosis in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An introduction to Markov modelling for economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling for health care and other policy decisions: uses, roles, and validity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980100-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80100-5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44442609&oldid=2023671286"